Press Releases for CYCC

Press Releases
Cyclacel Pharmaceuticals Receives Deficiency Notice From Nasdaq Global Select Market
Cyclacel Pharmaceuticals Announces Second Quarter 2009 Financial Results
Cyclacel Pharmaceuticals to Announce Second Quarter 2009 Financial Results On August 6, 2009
Cyclacel Completes Previously Announced Registered Direct Offering
Cyclacel to Raise Up to $5.9 Million in Registered Direct Offering
FiSpace.Net Releases Tuesday Watch List for MEXP, MPG, CYCC, SRS, PGV, FAZ
Cyclacel to Present At Annual Needham Biotechnology and Medical Technology Conference
Sapacitabine Has Anti-Cancer Activity in Combination With Targeted Agents and Other Nucleoside Analogs
Cyclacel Reports Initial Phase 2 Seliciclib Data in Patients With Nasopharyngeal Carcinoma At 2009 ASCO Annual Meeting
Cyclacel Reports Phase 2 Sapacitabine Data in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes At 2009 ASCO Annual Meeting
Cyclacel Pharmaceuticals Reports Financial Results for First Quarter 2009
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2009 Financial Results and Upcoming Corporate Events
Cyclacel & Dartmouth Researchers Report Novel Mechanism of Action for Seliciclib At AACR
Cyclacel Pharmaceuticals Announces Multiple Presentations At American Association of Cancer Research Annual Meeting
Cyclacel Pharmaceuticals Announces Suspension of Quarterly Dividend On 6% Convertible Exchangeable Preferred Stock
Cyclacel Pharmaceuticals Announces Financial Results for Fourth Quarter and Year Ended December 31, 2008
Cyclacel Pharmaceuticals to Announce Fourth Quarter 2008 Financial Results On March 31, 2009
Cyclacel Announces Phase 1 Data Published Elucidating Pharmacodynamics & Mechanism of Action of Seliciclib in Nasopharyngeal Cancer
Cyclacel Pharmaceuticals Advances Oral Sapacitabine Pivotal Trial Plan in Hematological Malignancies
Cyclacel Pharmaceuticals to Present At BIO CEO & Investor Conference
Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Cyclacel Pharmaceuticals to Present At Two Upcoming Investor Conferences
Cyclacel Pharmaceuticals to Present At Rodman & Renshaw 10th Annual Healthcare Conference
Cyclacel Pharmaceuticals Announces Third Quarter 2008 Financial Results
Cyclacel Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 6, 2008
Cyclacel Pharmaceuticals to Present at BIO Investor Forum
Cyclacel to Present Preclinical Data Showing Synergy of Combination of Sapacitabine with Histone Deacetylating Agents
Cyclacel Announces Completion of Enrollment in Phase 2 Trial of Sapacitabine in Elderly AML
Cyclacel Announces Revised Operating Plan & Refocused Resources
Cyclacel Expands Phase 2 Sapacitabine Trial in Elderly AML to Include Patients With MDS
Cyclacel Appoints Nicholas Bacopoulos, Ph.D. to Board of Directors
Cyclacel Announces Recommendations of Data Review Committee for Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial
Cyclacel Pharmaceuticals Announces Second Quarter 2008 Financial Results
Cyclacel to Present At the Canaccord Adams Global Growth Conference
Cyclacel Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 7, 2008
Cyclacel Publishes Study of Seliciclib Synergy with Tarceva and Herceptin in Journal Clinical Cancer Research
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Cyclacel to Present at Collins Stewart Fourth Annual Growth Conference
Cyclacel to Present at Annual Needham Biotechnology & Medical Technology Conference
Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 Combination Study of Seliciclib and Tarceva(R) in Advanced Cancers
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Cyclacel Pharmaceuticals to Present at Investment Banking Conferences During May 2008 - May 27 2008 12:54AM
Cyclacel Pharmaceuticals Announces First Quarter 2008 Financial Results - Jun 1 2008 5:15PM
Cyclacel Pharmaceuticals, Inc. (CYCC) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Cyclacel Pharmaceuticals Announces May 2008 Corporate Events
Cyclacel Pharmaceuticals Presents Insights into the Mechanisms of Its Cell Cycle Inhibitor Drugs
Cyclacel Pharmaceuticals Announces Multiple Presentations at American Association of Cancer Research Annual Meeting